

Change in number of shares and votes in Episurf Medical

Episurf Medical AB (NASDAQ: EPIS B) has, by information previously announced, conducted a directed share issue. Through the new issue, the number of shares has increased by 3,290,210 B-shares and the number of votes has increased by the same amount.

On behalf of shareholders in Episurf Medical AB, conversions of class A-shares to B-shares were carried out during January in accordance with the Articles of Association. Through the conversions, the number of A-shares has decreased by 4,601,519, and the number of B-shares has increased by the same amount.

Episurf Medical AB has also performed conversion of convertible bonds issued under the financing agreement published on February 23, 2018. The number of convertibles converted in January was 10. The number of convertibles remaining under the first tranche for future conversion is 48. Through the conversion, the number of shares increased by 192,307 B-shares and, the number of votes has increased by the same amount. The terms of the convertibles are published on Episurf Medical AB's website.

The total number of shares amounts to 35,113,686, of which 620,143 are A-shares and 34,493,543 are B-shares. The total number of votes after the conversions amounts to 36,353,972.

For more information, please contact:

Veronica Wallin, CFO, Episurf Medical
Tel: +46 (0) 700 37 48 95
Email: veronica.wallin@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical's Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical's µFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.

This information is information that Episurf Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 11:00 CET on January 31, 2019.